Corvus Pharmaceuticals Inc (OQ:CRVS)

Business Focus: Biotechnology & Medical Research

May 06, 2024 04:01 pm ET
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024. “We...
May 02, 2024 04:02 pm ET
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on May 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report...
May 02, 2024 08:30 am ET
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with new and existing investors to raise...
Apr 09, 2024 04:01 pm ET
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the initiation of the Company’s randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with...
Mar 19, 2024 04:02 pm ET
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31,...
Mar 13, 2024 04:02 pm ET
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 19, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report...
Feb 12, 2024 08:30 am ET
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on...
Feb 08, 2024 04:05 pm ET
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for soquelitinib for the treatment of T cell lymphoma....
Feb 06, 2024 04:05 pm ET
Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Arcara as Chief Business Officer. Mr. Arcara, who is a proven leader with more than 30 years of commercial...
Jan 23, 2024 05:00 pm ET
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, is deeply saddened to announce the passing of Edith P. Mitchell, M.D., a valued member of the Board of Directors. The Company extends its condolences to her...
Dec 09, 2023 12:00 pm ET
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from its Phase 1/1b clinical trial of soquelitinib in patients with relapsed PTCL. Soquelitinib demonstrated durable...
Nov 07, 2023 04:01 pm ET
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2023. “We continue to...
Nov 02, 2023 09:15 am ET
Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new interim data from its Phase 1/1b trial of soquelitinib in patients with relapsed peripheral T cell lymphoma (PTCL), at...
Nov 01, 2023 07:31 pm ET
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data that demonstrated the potential of ITK inhibition as a novel approach to treat T cell-mediated inflammatory...
Oct 31, 2023 04:02 pm ET
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 7, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report...
Sep 06, 2023 04:05 pm ET
Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, confirmed today that it completed an End-of-Phase/Pre-Phase 3 meeting with FDA on its plans to initiate a Phase 3 registrational clinical trial of soquelitinib...
Aug 08, 2023 04:01 pm ET
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2023. “During the second...
Aug 01, 2023 08:30 am ET
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 8, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report...
Jul 06, 2023 12:59 pm ET
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data on soquelitinib (formerly known as CPI-818), the Company’s ITK inhibitor product candidate, which...
Jun 29, 2023 07:00 am ET
Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced new preclinical data for ciforadenant, the Company’s adenosine 2A receptor inhibitor, highlighting its mechanism of action and synergy with...
Jun 15, 2023 07:00 am ET
Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced new data for CPI-818, the Company’s ITK inhibitor, demonstrating the potential to treat a variety of solid and hematological cancers based on a...
Jun 06, 2023 10:55 am ET
Thinking about buying stock in Corvus Pharmaceuticals, Limbach, Crinetics Pharmaceuticals, EnerSys, or Hubbell?
NEW YORK, June 6, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRVS, LMB, CRNX, ENS, and HUBB.
May 31, 2023 08:30 am ET
Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer of Corvus, will conduct one-on-one meetings with investors and present a...
May 18, 2023 11:40 am ET
Thinking about buying stock in Upstart, Corvus Pharmaceuticals, BlackBerry, IONQ, or Opendoor Technologies?
NEW YORK, May 18, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for UPST, CRVS, BB, IONQ, and OPEN.
May 17, 2023 09:00 am ET
Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data for CPI-818, the Company’s ITK inhibitor, at the International Conference on Malignant Lymphoma (ICML) meeting,...
May 08, 2023 04:01 pm ET
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the quarter ended March 31, 2023. “We continue to focus on...
Apr 20, 2023 09:00 am ET
Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on May 8, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report...
Apr 17, 2023 09:00 am ET
Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) A
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced new data for CPI-818, the Company’s ITK inhibitor, demonstrating its potential to treat a variety of solid and hematological cancers based on a...
Apr 03, 2023 08:30 am ET
CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced interim data demonstrating the potential of CPI-818, the Company’s ITK inhibitor, for the treatment of T cell lymphoma (TCL) at the 10th...
Mar 28, 2023 04:02 pm ET
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2022. “Heading...
Mar 21, 2023 04:05 pm ET
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on March 28, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report...
Mar 14, 2023 04:35 pm ET
Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data for CPI-818, the Company’s ITK inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting,...
Feb 21, 2023 07:00 am ET
Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new data demonstrating the potential of CPI-818, the Company’s ITK inhibitor, to reduce the need for chronic human...
Dec 12, 2022 10:00 am ET
Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced updated results from its Phase 1/1b trial of CPI-818, the Company’s ITK inhibitor, which demonstrated its anti-tumor...
Dec 05, 2022 08:30 am ET
Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will host an investor conference call to provide an update on CPI-818 data that will be presented at the 64th...
Nov 14, 2022 08:30 am ET
James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology
James T. Rosenbaum, MD, Senior Vice President of Research at Corvus Pharmaceuticals (Nasdaq: CRVS), was presented with the Distinguished Service Award by the American College of Rheumatology (ACR) at its annual meeting in Philadelphia on November...
Nov 03, 2022 04:05 pm ET
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2022. "We anticipate several...
Nov 03, 2022 09:52 am ET
Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data from its Phase 1/1b trial of CPI-818, the Company’s ITK inhibitor, at the 64th American Society of Hematology...
Oct 27, 2022 04:05 pm ET
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on November 3, 2022 at 4:30 pm ET (1:30 pm PT) to provide a business update and report...
Oct 25, 2022 04:05 pm ET
Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 1b/2 clinical trial evaluating ciforadenant as a potential first line therapy for metastatic...
Sep 26, 2022 04:05 pm ET
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application to initiate a Phase 1/1b clinical trial of mupadolimab (formerly CPI-006) has been approved by...
Sep 06, 2022 04:05 pm ET
Corvus Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference, which is taking place September...
Aug 08, 2022 04:05 pm ET
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2022. “We continue to see...
Jul 28, 2022 04:05 pm ET
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 8, 2022
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on August 8, 2022 at 4:30 pm ET (1:30 pm PT) to provide a business update and report...
Jul 21, 2022 04:05 pm ET
Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of James Rosenbaum, M.D. as Senior Vice President of Research, effective immediately. His initial focus...
May 10, 2022 07:30 am ET
Corvus Pharmaceuticals Provides Program Updates at R&D Symposium
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, is hosting an R&D Symposium today in New York City. During the event, which will also be available via webcast, the Company plans to...
May 05, 2022 04:05 pm ET
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the quarter ended March 31, 2022. “We are advancing our three...
Apr 26, 2022 07:30 am ET
Corvus Pharmaceuticals to Host R&D Symposium on May 10, 2022 in New York
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will host an R&D Symposium to provide an update on the Company’s three clinical programs. The event will be...
Mar 10, 2022 04:05 pm ET
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2021. “We continue...
Mar 03, 2022 04:30 pm ET
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on March 10, 2022 at 4:30 pm ET (1:30 pm PT) to provide a business update and report...
Jan 13, 2022 06:30 pm ET
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has treated the first patient in its Phase 1/1b...
Dec 13, 2021 09:00 am ET
New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as a Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new preclinical data demonstrating the potential of CPI-818, the company’s ITK inhibitor, for the prevention and therapy of acute graft versus...
Nov 12, 2021 07:00 am ET
Corvus Pharmaceuticals Presents Updated Data from Mupadolimab (Anti-CD73) Phase 1/1b Clinical Trial at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced updated results from its Phase 1/1b clinical trial of mupadolimab (formerly CPI-006), a humanized monoclonal antibody directed against CD73...
Nov 10, 2021 04:05 pm ET
Corvus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies London Healthcare Conference, which is taking place November 16-19, 2021. The Company will conduct...
Nov 02, 2021 04:05 pm ET
Corvus Pharmaceuticals to Present Updated Mupadolimab (Anti-CD73) Data at 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present data from its Phase 1/1b trial of mupadolimab at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting,...
Nov 01, 2021 04:05 pm ET
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2021. “Corvus is a leader in the development of...
Oct 27, 2021 04:05 pm ET
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application submitted by its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has been approved by the Center for Drug...
Oct 25, 2021 07:30 pm ET
Angel Pharmaceuticals Announces Approval of IND Application in China for ITK Inhibitor CPI-818
JIAXING, China and BURLINGAME, Calif., Oct. 25, 2021 /PRNewswire/ -- Angel Pharmaceuticals Co., Ltd. ("Angel Pharma") today announced that its IND application for CPI-818, a small molecule ITK inhibitor, has been approved by the Center for Drug Evaluation (CDE) to initiate clinical trials in patients with relapsed/refractory T-cell lymphomas (TCL) in China.
Sep 22, 2021 06:00 am ET
Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious Disease
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided an update on its development programs in oncology and infectious disease for mupadolimab (formerly CPI-006), a humanized monoclonal antibody...
Sep 20, 2021 08:30 am ET
Thinking about buying stock in Verastem, Corvus Pharmaceuticals, Aprea Therapeutics, Spectrum Pharmaceuticals, or SmileDirectClub?
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VSTM, CRVS, APRE, SPPI, and SDC.
Sep 17, 2021 08:30 am ET
Thinking about buying stock in Corvus Pharmaceuticals, AbCellera Biologics, Rekor Systems, SmileDirectClub, or Arcus Biosciences?
NEW YORK, Sept. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRVS, ABCL, REKR, SDC, and RCUS.
Sep 07, 2021 04:05 pm ET
Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company’s management will participate in two upcoming investor conferences in September: The first conference is the H.C. Wainwright...
Aug 16, 2021 05:00 pm ET
Corvus Pharmaceuticals Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-818 in China
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that an IND application submitted by its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), for the initiation of a Phase 1/1b...
Aug 02, 2021 04:05 pm ET
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2021. “We continue to advance mupadolimab, our anti-CD73...
Jul 15, 2021 04:05 pm ET
Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has discontinued its Phase 3 study of mupadolimab for COVID-19 due to positive trends exhibited by COVID-19 vaccines in lowering...
May 25, 2021 04:05 pm ET
Corvus Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies Virtual Healthcare Conference. The presentation will be on Thursday, June 3, 2021 from 4:00-4:25 pm ET....
May 05, 2021 09:00 am ET
Corvus Pharmaceuticals Completes Sale of $10 Million Through Its ATM Program
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has completed the sale of approximately $10 million of its common shares pursuant to the Company’s ATM program established on March 9,...
Apr 29, 2021 04:05 pm ET
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2021. “In the first quarter we initiated our...
Mar 25, 2021 08:30 am ET
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2020. “In 2020, we made considerable...
Mar 05, 2021 08:30 am ET
Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company’s management will participate in two upcoming investor conferences in March: The first conference will be the H.C. Wainwright...
Feb 18, 2021 07:30 am ET
Thinking about buying stock in Avinger, Rigel Pharmaceuticals, Vistagen Therapeutics, Bio-Path, or Corvus Pharmaceuticals?
NEW YORK, Feb. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVGR, RIGL, VTGN, BPTH, and CRVS.
Feb 17, 2021 04:10 pm ET
Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the completion of its previously announced underwritten public offering of 9,783,660 shares of its common stock, which includes 1,212,231 shares...
Feb 12, 2021 09:00 am ET
Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 8,571,429 shares of its common stock at a price to the public of $3.50 per share, for gross...
Feb 11, 2021 04:01 pm ET
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be...
Feb 04, 2021 07:30 am ET
Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has initiated a Phase 3 clinical trial of CPI-006 for the treatment of hospitalized patients with COVID-19. The study is expected to...
Dec 06, 2020 10:00 am ET
Corvus Presents New Data on its Investigational ITK Inhibitor CPI-818 at the American Society of Hematology (ASH) Annual Meeting & Exposition
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that new data on CPI-818, the Company’s ITK inhibitor, were presented at the 62nd American Society of Hematology (ASH) Annual Meeting &...
Nov 30, 2020 08:00 am ET
Corvus Announces Upcoming CPI-818 Data Presentations at the American Society of Hematology (ASH) Annual Meeting & Exposition
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that new data on CPI-818, the Company’s ITK inhibitor, will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting &...
Nov 11, 2020 04:05 pm ET
Corvus Hosting R&D Symposium on November 12 to Highlight COVID-19 Program and Updated Study Data Presented at SITC Annual Meeting
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it is hosting an R&D Symposium on November 12, 2020 from 11:00 am - 1:00 pm ET (8:00 - 10:00 am PT) to highlight its COVID-19 program...
Nov 09, 2020 08:05 am ET
Corvus Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has completed patient enrollment in its Phase 1 study investigating the potential for CPI-006 to provide a novel immunotherapy approach...
Nov 02, 2020 08:00 am ET
Corvus Pharmaceuticals COVID-19 Abstract Selected for “Hot Topic” Oral Session at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its abstract covering updated data from its Phase 1 study investigating the potential for CPI-006 to provide a novel immunotherapy...
Oct 29, 2020 04:00 pm ET
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and announced financial results for the third quarter ended September 30, 2020. “We have several important milestones for...
Oct 29, 2020 08:30 am ET
Corvus Pharmaceuticals to Present Updated Data from its Clinical Trial of CPI-006 for Patients with COVID-19 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present updated data from its Phase 1 study investigating the potential for CPI-006 to provide a novel immunotherapy approach for...
Oct 05, 2020 07:24 am ET
Corvus Pharmaceuticals Announces Co-Founding of Angel Pharmaceuticals in China
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has entered into a strategic collaboration with Angel Pharmaceuticals that will enable the development and commercialization of its...
Oct 05, 2020 07:22 am ET
New Data from Corvus Phase 1 Study of CPI-006 Continues to Support its Potential as a Treatment for COVID-19
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced updated data from its ongoing Phase 1 study investigating the potential for CPI-006 to provide a novel immunotherapy approach for patients with...
Sep 17, 2020 03:01 am ET
New Data from Ciforadenant Phase 1b/2 Clinical Study Presented at ESMO Virtual Congress 2020
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that new data from its clinical collaboration with Genentech, which is being conducted under Genentech’s MORPHEUS umbrella program, will be...
Sep 11, 2020 08:30 am ET
Corvus Pharmaceuticals Appoints Edith Mitchell, M.D., to Board of Directors
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Edith P. Mitchell, M.D., has been appointed to the company’s Board of Directors. Dr. Mitchell has more than 45 years of experience...
Sep 10, 2020 08:30 am ET
Corvus Pharmaceuticals Provides Update on Clinical Trial of CPI-006 for Patients with COVID-19
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced updated data from its ongoing Phase 1 study investigating the potential for CPI-006 to provide a novel immunotherapy approach for patients with...
Sep 08, 2020 06:02 pm ET
Corvus Announces Participation in Upcoming Investor Conferences
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the following investor conferences: HC Wainwright 22nd Annual Investment Conference on September 14, 2020 at 4:00 pm...
Aug 04, 2020 04:05 pm ET
Corvus Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference. The presentation will be on Tuesday, August 11 from 2:55-3:25pm...
Jul 30, 2020 04:02 pm ET
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and announced financial results for the second quarter ended June 30, 2020. “In the second quarter, we advanced each of our...
Jul 23, 2020 08:30 am ET
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2020 Financial Results on July 30, 2020
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on July 30, 2020 at 4:30 pm ET (1:30 pm PT) to provide a business update and report...
Jul 07, 2020 10:45 am ET
Thinking about buying stock in Annovis Bio, Corvus Pharmaceuticals, MGM Resorts, PDS Biotechnology, or Remark Holdings?
NEW YORK, July 7, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ANVS, CRVS, MGM, PDSB, and MARK.
Jul 07, 2020 07:00 am ET
Corvus Pharmaceuticals Initiates Clinical Trial of Novel Immunotherapy for Patients with COVID-19
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19. The first cohort of five...
May 29, 2020 08:00 am ET
Corvus Pharmaceuticals Presents Updated Clinical Data Supporting and Refining the Adenosine Gene Signature’s Ability to Identify Patients Likely to Respond to Treatment with Ciforadenant
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection,...
May 27, 2020 08:00 am ET
Corvus Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection,...
May 13, 2020 05:23 pm ET
Corvus Pharmaceuticals to Present Data on Refinement of the Adenosine Gene Signature and Ciforadenant in Renal Cell Cancer at the ASCO20 Virtual Scientific Program
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection,...
Apr 30, 2020 04:05 pm ET
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection,...
Apr 22, 2020 08:30 am ET
Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2020 Financial Results on April 30, 2020
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection,...
Mar 05, 2020 04:05 pm ET
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection,...
Feb 28, 2020 04:01 pm ET
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter 2019 Financial Results on March 5, 2020
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the Company will host a conference call and...
Feb 19, 2020 04:05 pm ET
Richard Miller Awarded 2020 Drug Hunter Award by UC Drug Discovery Consortium
Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology...
Feb 13, 2020 08:00 am ET
Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1b/2 Clinical Trial of Ciforadenant at the 2020 American Society of Clinical Oncology’s Genitourinary Cancers Symposium
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced updated results...
Feb 01, 2020 02:00 pm ET
Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1/1b Clinical Trial of CPI-818 at the 12th Annual T-Cell Lymphoma Forum
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced updated results...
Dec 07, 2019 09:00 am ET
Corvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase 1/1b Trial of CPI-818 at the American Society of Hematology (ASH) Annual Meeting
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced initial results...
Nov 08, 2019 07:00 am ET
Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced updated...
Nov 07, 2019 08:30 am ET
Corvus Pharmaceuticals to Present Preclinical and Early Clinical Data from the Phase 1/1b Trial with CPI-818 at the American Society of Hematology (ASH) Annual Meeting
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced that it...
Nov 05, 2019 08:30 am ET
Corvus Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced that the...
Nov 04, 2019 08:30 am ET
Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 8, 2019
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced that it...
Oct 29, 2019 04:05 pm ET
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today provided a business update and reported financial results for...
Oct 17, 2019 08:30 am ET
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2019 Financial Results on October 29, 2019
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the Company will host a conference call and...
Oct 03, 2019 08:30 am ET
Corvus Pharmaceuticals to Present Updated Data from CPI-006 Clinical Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present data from its Phase 1/1b...
Aug 07, 2019 04:05 pm ET
Corvus Pharmaceuticals to Present at the 2019 Wedbush Healthcare Conference
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present at the 2019 Wedbush Healthcare...
Aug 01, 2019 04:05 pm ET
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2019 Financial Results
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today provided a business update and reported financial results for...
Jul 24, 2019 04:15 pm ET
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2019 Financial Results on August 1, 2019
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the Company will host a conference call and...
Jun 02, 2019 10:45 am ET
Corvus Pharmaceuticals Presents Initial CPI-006 Phase 1/1b Clinical Data at 2019 ASCO Annual Meeting
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced initial results from its Phase 1/1b trial of CPI-006,...
May 28, 2019 08:30 am ET
Corvus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present at the Jefferies 2019 Global...
May 16, 2019 08:30 am ET
Corvus Pharmaceuticals to Present Initial Clinical Data from CPI-006 Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present initial clinical data from its...
May 09, 2019 04:02 pm ET
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today provided a business update and announced financial results for...
May 01, 2019 04:10 pm ET
Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2019 Financial Results on May 9, 2019
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the Company will host a conference call and...
Apr 19, 2019 07:35 am ET
New Research Coverage Highlights EMCOR Group, Reven Housing REIT, Communications, Marine Products, Corvus Pharmaceuticals, and Energy Focus — Consolidated Revenues, Company Growth, and Expectations fo
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of EMCOR Group, Inc. (NYSE:EME), Reven Housing REIT, Inc. (NASDAQ:RVEN),...
Mar 07, 2019 04:10 pm ET
Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the fourth quarter and year...
Mar 05, 2019 04:15 pm ET
Corvus Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the Company will present at the Cowen and...
Feb 06, 2019 08:30 am ET
Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs CPI-444 and CPI-006 at Immuno-Oncology 360° Conference
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced the presentation of updated biomarker and clinical...
Jan 30, 2019 08:30 am ET
Corvus Pharmaceuticals to Present Updated Biomarker and Clinical Data on Lead Development Programs CPI-444 and CPI-006 at Immuno-Oncology 360° Conference
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present updated data from its lead...
Jan 28, 2019 04:05 pm ET
Corvus Pharmaceuticals Announces Appointment of New Member of Board of Directors and Hiring of Chief Medical Officer
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced the appointment of Linda S. Grais, M.D., J.D., to the...
Jan 10, 2019 08:30 am ET
Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced data from a preclinical study of CPI-818, its...
Jan 08, 2019 08:30 am ET
Corvus Announces Enrollment in Second Arm of Phase 1/1b Dose-Escalation Trial of Anti-CD73 Antibody, CPI-006, Focused on Combination with CPI-444 Adenosine Antagonist
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it has initiated patient enrollment in the...
Nov 13, 2018 07:30 am ET
Report: Exploring Fundamental Drivers Behind Berry Petroleum, Quotient, Virco Manufacturing, Corvus Pharmaceuticals, Marine Products, and Hamilton Beach Brands Holding — New Horizons, Emerging Trends,
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Berry Petroleum Corporation (NASDAQ:BRY), Quotient Limited (NASDAQ:QTNT),...
Nov 12, 2018 08:30 am ET
Corvus Pharmaceuticals to Present at the 27th Annual Credit Suisse Healthcare Conference
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the company will present at the 27th Annual...
Nov 10, 2018 05:00 pm ET
Corvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual Meeting
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced updated clinical and biomarker data from ongoing...
Nov 05, 2018 06:31 pm ET
Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 10, 2018
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, will be hosting an investor and analyst event on Saturday, November...
Nov 01, 2018 04:10 pm ET
Corvus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the third quarter ended...
Oct 22, 2018 08:30 am ET
Corvus Pharmaceuticals Announces New Data on Adenosine Gene Signature Biomarker Associated with Patient Response to CPI-444 at European Society for Medical Oncology (ESMO) 2018 Congress
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced new data on a biomarker associated with patient...
Oct 04, 2018 04:15 pm ET
Corvus Pharmaceuticals to Present Data on Lead Programs at the European Society for Medical Oncology (ESMO) 2018 Congress and the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present data from its lead programs,...
Oct 03, 2018 04:15 pm ET
Corvus Pharmaceuticals Announces Publication of Preclinical Results Highlighting Antitumor Activity of CPI-444 in Multiple Tumor Models both as Monotherapy and in Combination Studies
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced the publication of results of preclinical studies of...
Sep 25, 2018 04:15 pm ET
Corvus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the company will present at the Cantor...
Aug 02, 2018 04:15 pm ET
Corvus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the second quarter ended June...
Jul 31, 2018 04:15 pm ET
Corvus Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the company will present at the 2018 Wedbush...
Jun 28, 2018 08:30 am ET
Corvus Pharmaceuticals Announces Publication of Preclinical Study Results Demonstrating CPI-444 Antitumor Activity as Monotherapy and in Combination with Anti-PD-1 Therapy in Cancer Immunology, Immuno
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced publication of results of preclinical studies of...
May 30, 2018 04:15 pm ET
Corvus Pharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the company will present at the Jefferies 2018...
May 03, 2018 04:10 pm ET
Corvus Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the first quarter ended March...
Apr 26, 2018 08:30 am ET
Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced Cancer
Three-arm Trial Will Evaluate CPI-006 as Monotherapy, in Combination with CPI-444 Adenosine Antagonist and in Combination with Pembrolizumab
Mar 12, 2018 09:15 am ET
Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock
BURLINGAME, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that precisely target crucial enzymes and proteins in the immune...
Mar 08, 2018 09:04 am ET
Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
BURLINGAME, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that precisely target crucial enzymes and proteins in the immune...
Mar 07, 2018 04:06 pm ET
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock
BURLINGAME, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that precisely target crucial enzymes and proteins in the immune...
Mar 06, 2018 08:30 am ET
Corvus Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference 2018
BURLINGAME, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the company will present at the Cowen and...
Mar 01, 2018 04:10 pm ET
Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
BURLINGAME, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the fourth quarter and year ended...
Feb 01, 2018 08:30 am ET
Corvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling Pathway Inhibitor at 10th Annual T-Cell Lymphoma Forum
Company’s Investigational Small Molecule Inhibitor Demonstrates Safety and Activity in Canine Spontaneous T-Cell Lymphoma
Nov 11, 2017 05:45 pm ET
Corvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient Selection
– Clinical Data from Renal Cell Carcinoma Cohorts Presentedin Oral Session at SITC 32nd Annual Meeting –...
Nov 11, 2017 05:45 pm ET
Corvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient Selection
– Clinical Data from Renal Cell Carcinoma Cohorts Presentedin Oral Session at SITC 32nd Annual Meeting –
Nov 02, 2017 04:10 pm ET
Corvus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Clinical Program Update
BURLINGAME, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial results for the third quarter ended September 30, 2017, and provided a business update....
Nov 02, 2017 04:10 pm ET
Corvus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Clinical Program Update
BURLINGAME, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial results for the third quarter ended September 30, 2017,...
Sep 20, 2017 04:10 pm ET
Corvus Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
BURLINGAME, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will present at the 2017 Cantor Fitzgerald Global Healthcare Conference in New York City, New York. The presentation is scheduled for Wednesday, September 27, at 1:05 p.m. Eastern Time....
Aug 11, 2017 07:10 pm ET
Corvus Pharmaceuticals to Present at the 2017 Wedbush PacGrow Healthcare Conference
BURLINGAME, Calif., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will present at the 2017 Wedbush PacGrow Healthcare Conference in New York City, New York. The presentation is scheduled for Wednesday, August 16, at 1:20pm Eastern Time....
Aug 03, 2017 04:10 pm ET
Corvus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
BURLINGAME, Calif., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial results for the second quarter ended June 30, 2017, and provided a business update....
May 15, 2017 08:30 am ET
Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 in Renal and Lung Cancer at 2017 ASCO Annual Meeting
BURLINGAME, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present an oral abstract presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago, Illinois. The abstract for the presentation will be available on the ASCO website on May 17 at 5:00 p.m. ET.  Following are details for the oral presentation....
May 09, 2017 08:30 am ET
Corvus Pharmaceuticals and Monash University Enter into Exclusive License Agreement for Novel Immuno-Oncology Program
BURLINGAME, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company, announced today that it has licensed global rights to an undisclosed novel immuno-oncology program, which includes a lead product candidate, from Monash University....
May 04, 2017 04:10 pm ET
Corvus Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update
BURLINGAME, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial results for the first quarter ended March 31, 2017, and provided a business update....
Mar 20, 2017 08:30 am ET
Corvus Pharmaceuticals to Present Data That Advances the Understanding of the Adenosine Pathway in Immuno-Oncology, including New Clinical Data on CPI-444 at AACR 2017
BURLINGAME, Calif., March 20, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present interim data from its ongoing Phase 1/1b study of CPI-444 as a single agent and in combination with Genentech’s Tecentriq® (atezolizumab) in an oral plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2017, which is taking place April 1-5 in Washington, D.C. The Company will also present preclinical...
Jan 04, 2017 04:10 pm ET
Corvus Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference 2017
BURLINGAME, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will present at the 35th Annual J.P. Morgan Healthcare Conference 2017 in San Francisco. The presentation is scheduled for Thursday, January 12, at 8:00 a.m. Pacific Time....
Jan 03, 2017 04:10 pm ET
Corvus Pharmaceuticals Names Ian T. Clark, Former Genentech Chief Executive Officer, to Board of Directors
BURLINGAME, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS) today announced the appointment of Ian T. Clark, former chief executive officer and head of North American Commercial Operations at Genentech, Inc., to its Board of Directors....
Nov 03, 2016 04:10 pm ET
Corvus Pharmaceuticals Announces Third Quarter Financial Results and Provides Business Update
BURLINGAME, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial results for the third quarter and nine months ended September 30, 2016 and provided a business update....
Nov 02, 2016 08:30 am ET
Corvus Pharmaceuticals to Present at SITC’s 31st Annual Meeting
BURLINGAME, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced it will present preliminary clinical and biomarker data from its from its ongoing Phase 1/1b study of CPI-444 as a single agent, and in combination with Genentech’s TECENTRIQ® (atezolizumab), at the Society for Immunotherapy of Cancer’s (SITC) 31st Annual Meeting & Associated Programs taking place November 9 – 13 in National Harbor, Maryland....
Nov 01, 2016 08:30 am ET
Corvus Pharmaceuticals to Present at Credit Suisse 25th Annual Healthcare Conference
BURLINGAME, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that management will present at the Credit Suisse 25th Annual Healthcare Conference on Tuesday, November 8 at 10:30 a.m. MT in Scottsdale, Arizona....
Oct 10, 2016 07:00 am ET
Corvus Pharmaceuticals Announces Biomarker Findings from Phase 1/1b Study of Lead Oral Checkpoint Inhibitor CPI-444 Presented at ESMO 2016 Congress
BURLINGAME, Calif., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced biomarker findings from its ongoing Phase 1/1b study of CPI-444 as a single agent and in combination with Genentech’s TECENTRIQ® (atezolizumab),‎ a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1 (PD-L1). CPI-444 is a selective and potent inhibitor of the adenosine A2A receptor. The data were presented today in a po...
Oct 04, 2016 08:30 am ET
Corvus Pharmaceuticals to Present Data on Lead Oral Checkpoint Inhibitor CPI-444 at ESMO 2016 Congress
BURLINGAME, Calif., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present preclinical data and preliminary biomarker data from its ongoing Phase 1/1b study of CPI-444 as a single agent, and in combination with Genentech’s TECENTRIQ™ (atezolizumab), in poster presentation sessions at the European Society for Medical Oncology (ESMO) 2016 Congress, which is taking place October 7-11 at the Bella Center in Cop...
Sep 25, 2016 07:30 pm ET
Corvus Pharmaceuticals Announces Preclinical and Preliminary Clinical Biomarker Data of Lead Oral Checkpoint Inhibitor CPI-444 Presented at Second CRI-CIMT-EATI-AACR International Cancer Immunotherap
 --Preclinical Studies Demonstrate Activity of CPI-444 Both Alone and in Combination with Anti-PD-1 and Anti-PD-L1 Antibodies-- ...
Sep 19, 2016 08:30 am ET
Corvus Pharmaceuticals to Present Data on Lead Oral Checkpoint Inhibitor CPI-444 at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
BURLINGAME, Calif., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present preclinical data, and preliminary biomarker data from its ongoing Phase 1/1b study of CPI-444 as a single agent, and in combination with Genentech’s TECENTRIQ™ (atezolizumab)‎, in both oral and poster presentations at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, ...
Aug 04, 2016 04:10 pm ET
Corvus Pharmaceuticals Announces Second Quarter Financial Results and Provides Business Update
BURLINGAME, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), today announced financial results for the second quarter and six months ended June 30, 2016 and provided a business update....
Jul 06, 2016 08:30 am ET
Corvus Pharmaceuticals to Present at Cantor Fitzgerald’s Second Annual Healthcare Conference on July 12
BURLINGAME, Calif., July 06, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced management will present at the Cantor Fitzgerald Second Annual Healthcare Conference on July 12 at 11:45 a.m. EDT at Le Parker Meridien Hotel, New York....
Jun 29, 2016 08:30 am ET
Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer
BURLINGAME, Calif., June 29, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced it has named former Roche/Genentech Vice President, Global Head of Roche Oncology Business Development, Jason, V. Coloma, Ph.D., to the newly created post of Senior Vice President and Chief Business Officer....
Jun 17, 2016 08:30 am ET
Corvus Pharmaceuticals’ Ian McCaffery, PhD to Present at Rational Combinations 360° June 23-24, New York
BURLINGAME, Calif., June 17, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced Corvus’s Dr. Ian McCaffery will present at the inaugural Rational Combinations 360° event at the Park Lane Hotel, New York, June 23 – 24. ...
May 05, 2016 04:10 pm ET
Corvus Pharmaceuticals Announces First Quarter 2016 Financial Results
BURLINGAME, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial results for the three months ended March 31, 2016....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.